NextCure (FRA:2US) ROE % Adjusted to Book Value : -118.93% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure ROE % Adjusted to Book Value?

NextCure's ROE % for the quarter that ended in Mar. 2024 was -64.22%. NextCure's PB Ratio for the quarter that ended in Mar. 2024 was 0.54. NextCure's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -118.93%.

NextCure ROE % Adjusted to Book Value Historical Data

The historical data trend for NextCure's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure ROE % Adjusted to Book Value Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-11.81

-39.17

-161.21

-161.96

NextCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-153.08	-134.78	-155.46	-175.93	-118.93

Competitive Comparison of NextCure's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NextCure's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCure's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NextCure's ROE % Adjusted to Book Value falls into.

NextCure ROE % Adjusted to Book Value Calculation

NextCure's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-43.73%	/	0.27
	=	-161.96%

NextCure's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-64.22%	/	0.54
	=	-118.93%

NextCure ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NextCure's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (FRA:2US) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

NextCure (FRA:2US) Headlines

No Headlines